drugset / Trial / NCT03284853
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
RandomizedParallel-groupTriple-blindTreatment
Summary
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure
Timeline
- Start
- 2017-09-05
- Primary completion
- 2020-11-06
- Completion
- 2020-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bimatoprost | Other / unclassified | 0.03 % | Topical |
| Subject | Latanoprost | Small molecule | 0.005 % | Topical |
| Subject | Netarsudil | Small molecule | 0.02 % | Topical |
| Comparator | Timolol | Other / unclassified | 0.5 % | Topical |